Pioneer Pharmaceutical Biotechnology (00399.HK): The placement agreement has expired
Gelonghui, April 19 | Pilot Pharmaceutical Biotechnology (00399.HK) announced that since the prerequisites contained in the placement agreement were not fully reached or satisfied before April 18, 2024, the placement agreement has expired and the placement matters will not proceed.
Pilot Pharmaceutical Biotechnology (00399) plans to discount approximately 12.5% of up to 114 million shares to raise a net of HK$18.204 million
According to Zhitong Finance App, Pilot Pharmaceutical Biotechnology (00399) announced that on March 28, 2024, the company entered into a placement agreement with the placement agent. The placement agent has agreed to act as the company's agent to wholeheartedly induce no less than six undertakers (whose ultimate beneficial owner should be an independent third party) to subscribe for up to 114 million shares at an placement price of HK$0.175 per share. Assuming that the company's issued share capital will not change from the date of this announcement to the date of completion of the placement, the maximum number of placed shares of 114 million placed shares will account for the company that has been expanded through the allocation and issuance of all placed shares
Pilot Pharmaceutical Biotechnology (00399) issued 55 million shares due to the exercise of the right to convert convertible bonds
Pilot Pharmaceutical Biotechnology (00399) issued an announcement according to the exercise of convertible shares issued on April 30, 2015...
Pilot Pharmaceutical Biotechnology (00399.HK) received an additional 50 million shares of common stock worth approximately HK$10.5 million from Chow Yiu Ting
On January 9, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 9, Chow Yiu-ting increased her OTC share holdings of $Pilot Pharmaceutical Biotechnology (00399.HK) by $50 million at an average price of HK$0.21 per share, worth about HK$10.5 million on January 8. After the increase in holdings, Chow Yiu-ting's latest shareholding was 429 million shares, and the good position ratio increased from 22.70% to 25.69%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies.
Pilot Pharmaceutical Biotechnology (00399) issued approximately 99 million shares due to the conversion of convertible bonds
Pilot Pharmaceutical Biotechnology (00399) issued an announcement. The company issued on December 31, 2014 in accordance with the exercise...
Pilot Pharmaceutical Biotechnology (00399.HK) received an additional 50 million shares of common stock worth approximately HK$10.95 million from Chow Yiu Ting
On January 5, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 5, Chow Yiu-ting increased her OTC share holdings of $Pilot Pharmaceutical Biotechnology (00399.HK) by $50 million at an average price of HK$0.219 per share on January 2, worth about HK$10.95 million. After the increase in holdings, Chow Yiu-ting's latest shareholding was 379 million shares, and the good position ratio increased from 20.94% to 24.13%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies
領航醫藥生物科技:中期報告 2023-2024
Innovative Pharmaceutical Biotech Returns to Fiscal H1 Attributable Profit
Innovative Pharmaceutical Biotech (HKG:0399) returned to an attributable profit of HK$193.7 million in the first fiscal half from a loss of HK$115.7 million in the year-ago period, a Wednesday filing
Pilot Pharmaceutical Biotechnology (00399.HK)'s mid-term earnings of about HK$3.7 million decreased by about 9.7% year-on-year
Gelonghui November 29丨Pilot Pharmaceutical Biotechnology (00399.HK) announced that for the six months ended September 30, 2023, the company's revenue was approximately HK$3,700,000, a decrease of about 9.7% over the previous year. The decrease was mainly due to a decrease in the operations of the Beauty Equipment and Products Trading Division during the current financial period. The Group recorded a profit of approximately HK$193,700,000 attributable to company owners during the period, while a loss of HK$115,700,000 was recorded in the previous financial period. The conversion of losses to profits was mainly due to non-cash items arising from the completion of the third revision of Convertible Bonds III during the current financial period.
INNOVATIVE PHAR: ANNOUNCEMENT OF INTERIM RESULTSFOR THE SIX MONTHS ENDED 30 SEPTEMBER 2023
Innovative Pharmaceutical Biotech to Return to Profit in Fiscal H1
Innovative Pharmaceutical Biotech (HKG:0399) expects to book a profit attributed to shareholders of between HK$100 million and HK$200 million for the fiscal first half, turning around from the loss of
INNOVATIVE PHAR: Profit Alert
Pilot Pharmaceutical Biotechnology (00399.HK) will hold a board meeting on November 29 to approve the interim results
Gelonghui November 14|Pilot Pharmaceutical Biotechnology (00399.HK) announced that a board meeting will be held on November 29, 2023 to consider and approve the comprehensive interim results of the company and its subsidiaries for the six months ended September 30, 2023.
Innovative Pharmaceutical Eyes Majority Stake in US Neurotechnology Firm
Innovative Pharmaceutical Biotech (HKG:0399) is in negotiations to acquire a majority stake in US-based Niraxx, which is developing wearables for brain health and related disorders using non-invasive
Niraxx Develops At-Home, Self-Administered Brain Neurostimulation Hybrid Virtual Platform
Niraxx Develops At-Home, Self-Administered Brain Neurostimulation Hybrid Virtual Platform
Innovative Pharmaceutical to Issue Convertible Bonds to Acquire Stake
Innovative Pharmaceutical to Issue Convertible Bonds to Acquire Stake
Innovative Pharmaceutical Biotech Plans to Acquire a Majority Stake in U.S. Based Company Niraxx
Innovative Pharmaceutical Biotech Plans to Acquire a Majority Stake in U.S. Based Company Niraxx
Pilot Pharmaceutical Biotechnology (00399.HK): Termination of subscription agreement
GLONGHUI, September 4 | Pilot Pharmaceutical Biotechnology (00399.HK) announced that after further negotiations and discussions, the subscriber failed to fulfill its responsibilities under the subscription agreement. After considering (including) current market conditions, the company and subscribers have decided not to continue with the subscription matters. Having considered the above, on September 4, 2023, the company and the subscriberer entered into a deed of termination. Based on this, the contracting party to the subscription matter agreed that the subscription agreement would be terminated from September 4, 2023, and that all rights, rights, obligations and liabilities of the contracting party would be terminated, and that no contracting party could give to the other party arising out of or relating to the subscription agreement
INNOVATIVE PHAR: Annual Report 2023
Innovative Pharmaceutical Plans HK$55.5 Million Bond Issue
Innovative Pharmaceutical Biotech (HKG:0399) said it intends to offer HK$55.5 million worth of convertible bonds (CBs) to an independent stakeholder, Dr Mao Yu Min, in lieu of the debt, of a comparabl
No Data